Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Value Stocks to Buy for July 19th

by Zacks Equity Research

SOHO, DVA and PHM made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 19, 2023.

DaVita HealthCare (DVA) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Brookdale (BKD) Reports Occupancy Growth for 20 Straight Months

by Zacks Equity Research

The continuous uptick observed in Brookdale's (BKD) weighted average occupancy level is expected to inflict a favorable impact on its resident fee revenues in the days ahead.

Is DaVita (DVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

U.S. Physical Therapy (USPH) Surges 3.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

U.S. Physical Therapy (USPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Debanjana Dey headshot

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

DaVita HealthCare (DVA) Down 1.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Medtronic (MDT) to Expand Diabetes Care With New Buyout

by Zacks Equity Research

Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Thermo Fisher (TMO) Expands Manufacturing Facility in APAC

by Zacks Equity Research

Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.

QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory

by Zacks Equity Research

QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

by Zacks Equity Research

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

Abbott (ABT) Expands in Electrophysiology With New FDA Nod

by Zacks Equity Research

Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

by Zacks Equity Research

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

by Zacks Equity Research

Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

by Zacks Equity Research

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

Veeva Systems' (VEEV) New Launch to Improve Patient Outcomes

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.